GutID® vs. Viome: Strain-Level DNA vs. RNA Gut Testing

Ask whether metatranscriptomics beats long-read sequencing and you have quietly asked two different questions at once. One is about which molecule gets read. The other is about what the reading is for. The second question is the one that decides which report is useful in a clinic.

Anyone researching gut microbiome testing runs into the same head-to-head: Viome, which sequences RNA, versus platforms that sequence DNA. Viome draws a bright line here, arguing that DNA-based tests can tell you which organisms are present but not what those organisms are doing, or whether they are even alive.¹

It is a fair argument, and it is drawn against short-read 16S amplicon sequencing. Not every DNA method shares that method's limits. There is also a question the framing leaves open, and it applies equally to both approaches: a list is not an interpretation. A list of expressed genes is no more self-explanatory than a list of organisms. Something has to turn the data into a clinical read.

This post compares the two approaches on methodology and on what each one hands to the person who has to act on it. Where Viome's technology is genuinely stronger, we say so.

Two different questions, not two grades of the same answer

Every microbiome test is a trade. You choose an analyte, and the analyte determines the question you are allowed to ask.

What RNA measures: activity

Metatranscriptomics sequences the transcriptome, the pool of RNA a microbial community is actively producing. Because only living organisms transcribe RNA, its presence is evidence of metabolic activity. Viome's method, which the company calls Viomega, depletes ribosomal RNA and sequences what remains, quantifying microbial gene expression against a reference set of over 110,000 microbial genomes and roughly 100 million microbial genes.² The output is a functional readout: which metabolic pathways were switched on at the moment of collection.

That is real information, and DNA cannot give it to you directly. A gene can sit in a genome, fully intact and entirely silent. Only RNA reveals the difference.

What DNA measures: identity, and therefore structure

DNA answers who is present. The catch is resolution, and resolution depends almost entirely on how much DNA you read in one pass.

Conventional 16S sequencing reads a short slice of a single gene, typically a few hundred base pairs of one variable region. That is enough to name a genus, often a species, and almost never a strain. Long-read sequencing changed the arithmetic. Instead of a fragment, it captures the full ribosomal RNA operon (the 16S gene, the internal transcribed spacer, and the 23S gene) as one continuous read of roughly 4,500 base pairs.³

The ITS region is why this matters. It carries several times the sequence variability of the 16S coding region, pushing taxonomic resolution to the species and, in many cases, the strain level.⁴ Organisms short-read 16S cannot separate become distinguishable: Escherichia coli from Shigella, or members of the Streptococcus mitis group sharing more than 99% identity across the 16S gene alone.³

This is what GutID®'s Titan-1™ technology does: long-read ribosomal sequencing on PacBio HiFi chemistry, paired with a proprietary amplicon design and AI-driven analysis that generates a unique sequence fingerprint for each strain.⁵ It does this database-independently. Reference-based methods can only report organisms already sitting in their reference library, so anything novel is discarded or misassigned. Titan-1 fingerprints known and unknown strains alike, without sequencing whole genomes.⁶

Why strain identity is a functional claim, not merely a taxonomic one

Here is what the RNA-versus-DNA framing tends to skip.

Two strains of the same species can carry meaningfully different gene content and produce opposite effects in the gut. A commensal strain and a pathogenic strain may be indistinguishable at the species level. So a test reporting only "E. coli present" has not simply lost taxonomic precision. It has lost the functional information that mattered, because in that species the function lives at the strain.

Resolution, in other words, is not a vanity metric. It is the precondition for saying anything true about function from DNA.

But resolution is also not the destination.

Beyond detection. Understanding the ecosystem.™

The GutID Ecosystem Approach™: what the data is for

Detection is the substrate. It is not the product.

A report that names two thousand strains with perfect accuracy and stops there has handed the clinician a census, not a clinical picture. The same is true of a report listing several hundred upregulated pathways. Both are inventories. Neither tells a practitioner what is structurally wrong with the community, or what to do about it.

The GutID Ecosystem Approach™ reframes results from individual organisms to ecosystem structure: how the community is organized, where its balance has shifted, which relationships have broken, and whether the system retains the resilience to recover. Strain-level identity is what makes that reading possible, because you cannot describe the structure of an ecosystem you can only resolve to the genus.

One consequence of this framing is worth stating plainly, because it cuts against how most microbiome reports are sold: diversity is a summary statistic, not a verdict. More diversity is not automatically better. A community can be diverse and disordered. It can be less diverse and entirely healthy. Reading a single diversity index as a grade is precisely the reductionism the Ecosystem Approach™ is built to replace.

The two framings point in opposite directions. An expression-first reading looks past the organism and down to the gene. The Ecosystem Approach™ looks past the organism and up to the community. Both are moving away from the single-organism view. They disagree about which way to go, and we think the community is the level at which gut health actually behaves.

GutID vs. Viome: a methodology comparison

Where metatranscriptomics is genuinely the stronger tool

If your question is what is this community doing right now, meaning which pathways are upregulated, how expression shifts after a dietary change, or whether a metabolic function is active rather than merely encoded, then RNA is the correct analyte and DNA is not a substitute. Metatranscriptomics captures temporal dynamics a DNA census cannot see, and only a subset of a community's functional potential is expressed at any given moment.⁹

For interventional research, longitudinal expression studies, and mechanistic work, that is exactly the readout you want. We would not pretend otherwise.

The trade-offs of an RNA-based approach

These trade-offs are well documented, including by the developers of the method itself. The team behind Viomega opens its published methods paper by acknowledging that stool metatranscriptomics has rarely been used in clinical studies because of complexity, cost, and bioinformatic burden, and that the method has drawn criticism over intra-sample variability, rapid change, and RNA degradation.⁷ Viomega was engineered to mitigate those problems, including ambient-temperature sample preservation.²

Those mitigations are meaningful. The underlying properties of the analyte, however, remain. Three hold for any RNA-based method:

• mRNA is short-lived. Microbial transcripts have brief half-lives, are subject to enzymatic degradation, and host RNA readily contaminates the pool.¹²
• Expression is a snapshot. The metatranscriptome shifts with diet, circadian timing, and recent stress. It is more dynamic and more subject-specific than the metagenome.⁹ Two samples from the same person on two mornings can legitimately differ.
• Transcript is not protein. Detecting mRNA is a poor predictor of function at the protein level, and the presence of a transcript does not guarantee the presence of the enzyme.¹²

For a research instrument, dynamism is the point. For a test a clinician wants to repeat in twelve weeks and read against a baseline, it is noise. DNA-based profiling has the opposite property: the gut metagenome is temporally stable and so personalized that repeat samples from one subject cluster together even against a background of hundreds of others.⁸ That stability is what allows a before-and-after comparison to mean something, and it is what makes measuring an intervention possible at all.

The distinction almost nobody makes: who reads the report

Both products are wellness tests. Neither is FDA-cleared as a diagnostic. Viome states plainly that its Gut Intelligence Test is not meant to identify or diagnose conditions.¹¹ The same is true of GutID. Neither should be presented as one.

The real divergence is architectural. Viome routes results through an app and an AI recommendation engine directly to the consumer, paired with personalized supplement subscriptions. GutID routes results through a clinician. The reports are built for practitioner interpretation and integration into a care plan, produced in a CLIA-certified, CAP-accredited laboratory,¹⁰ and structured around the Ecosystem Approach™ so that a trained reader can see where the community has lost its balance rather than scanning a ranked list of foods.

That difference decides which test is right for you more often than the sequencing chemistry does. It is a question about how you want your results read, not about sequencing chemistry.

So which should you choose?

Choose metatranscriptomics if you want a functional snapshot of expression, you are comfortable with a direct-to-consumer app experience and a supplement subscription, and you accept that your result reflects one particular morning.

Choose GutID if you want to know precisely which organisms are in your gut, down to the strain, including strains no reference database has catalogued, read as an ecosystem rather than a list, with a stable, reproducible result a clinician can interpret and re-test against a baseline. For irritable bowel symptoms, bloating, and persistent digestive complaints being worked up with a practitioner, strain-level structure is usually the missing variable.

These approaches are not mutually exclusive, and the field will likely converge on both. Today, if the report has to be reproducible and read by a professional, precision of identity is the foundation, and ecosystem interpretation is what turns that foundation into a clinical decision.

Further reading: How Titan-1™ technology works · Why strain-level testing matters · Clinician partnerships

Frequently asked questions

Is metatranscriptomics better than long-read sequencing for gut health?

Neither is universally better, because they measure different things. Metatranscriptomics reads RNA and reports which microbial genes are being expressed. Long-read DNA sequencing reads much longer stretches in a single pass and reports which organisms are present, at far higher taxonomic resolution than short-read 16S. The right choice depends on whether you need functional activity or precise identity, and on whether the report will be read by a consumer app or a clinician.

What is the GutID Ecosystem Approach™?

It is GutID's interpretive framework for reading a microbiome report. Rather than evaluating organisms one at a time, it reframes results in terms of ecosystem structure: how the community is organized, where balance has shifted, and whether the system retains resilience. Strain-level resolution from Titan-1™ long-read ribosomal sequencing is what makes that reading possible.

Does RNA sequencing identify bacteria more accurately than DNA sequencing?

Not inherently. Accuracy of identification depends on how much sequence information is available to distinguish organisms. Reading the full 16S-ITS-23S rRNA operon (~4,500 bp) provides substantially more discriminating information than the short 16S fragments used by conventional tests, enabling species- and strain-level resolution.³

Is higher microbiome diversity always better?

No. Diversity is a summary statistic, not a verdict. A community can be diverse and disordered, or less diverse and healthy. Structure, balance, and resilience carry more clinical information than any single diversity index.

Can a DNA test tell whether bacteria are alive?

Not directly. This is a legitimate advantage of RNA-based methods, since transcription requires a living organism. In practice, DNA from dead cells degrades in the gut environment, and clinical interpretation weighs relative abundance and ecosystem structure rather than viability alone.

What is 16S-ITS-23S sequencing?

It is the sequencing of the complete ribosomal RNA operon, comprising the 16S gene, the internal transcribed spacer, and the 23S gene, as one continuous long read of roughly 4,500 base pairs. The ITS region carries far more variability than 16S alone, which is what pushes resolution down to species and strain.^3,4

Are GutID and Viome diagnostic tests?

No. Both are wellness tests. Neither is cleared or approved by the FDA as a diagnostic device, and neither should be used to diagnose, treat, cure, or prevent disease.¹¹

All trademarks are the property of their respective owners. Viome™ and Gut Intelligence™ are trademarks of Viome Life Sciences, Inc.; references here are nominative and descriptive, based on publicly available company statements and peer-reviewed literature as of July 2026. GutID® is a registered trademark of Intus Biosciences, LLC. Titan-1™, GutID Ecosystem Approach™, and Beyond detection. Understanding the ecosystem.™ are trademarks of Intus Biosciences, LLC. GutID is a wellness test and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration. Consult a qualified healthcare provider regarding any medical condition.